Quantcast

Latest Tobacco cessation Stories

2008-09-14 03:00:10

By Manley, Harold J Stack, Nicole M Cigarette smoking is a readily modifiable cardiovascular and chronic kidney disease (CKD) risk factor. Smoking cessation aids include nicotine replacement therapy (NRT), bupropion, and varenicline. Several reports suggest that patients with CKD who use tobacco products be encouraged to stop; however, very little is offered to the healthcare provider as to how to successfully prescribe and monitor smoking cessation therapy for this patient population. This...

2008-09-11 03:00:24

HAMBURG, Germany, Sept. 11, 2008 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (Nasdaq:EVTC) announced today the start of the Phase II proof-of-concept study, investigating the effect of EVT 302 on the quit rate of patients who want to stop smoking. The Company also provided an analysis of the results of its exploratory Phase II craving study of the same compound. EVT 302 is a reversible and highly selective inhibitor of monoamine oxidase B (MAO-B). The completed double-blind, placebo...

2008-07-30 15:01:17

New full data from a 52-week, Pfizer-sponsored study demonstrated no significant difference in six-month and one-year quit rates between a nicotine replacement therapy patch and Pfizer's Chantix. Although these results are disappointing for Pfizer, they open up the market to developmental vaccine treatments which are able to demonstrate greater safety and efficacy than available options. The 52-week, Pfizer-sponsored study involved 746 participants who were randomized to receive either 12...

2008-07-28 09:01:47

PITTSBURGH, July 28 /PRNewswire/ -- New data published today in the August issue of Thorax shows no significant differences in 6-month and 1-year quit rates between the NicoDerm(R) CQ(R) Clear Patch and Chantix (varenicline tartrate) despite statistically higher quit rates for Chantix (varenicline tartrate) at 12 weeks. According to the official 2008 U.S. Public Health Service Guideline, longer-term quit rates at the 6-month milestone are the most predictive of long-term success. The...

2008-07-20 03:00:43

By Arnold, Matthew PFIZER FOLLOWED Eli Lilly's lead in posting a list of $10 million in grants and charitable contributions the company made to medical, scientific and patient organizations during the first quarter of 2008 as "part of an ongoing drive throughout the company to increase transparency." The disclosures include medical education grants, fellowship and scholarship support for institutions, grants to patient organizations, medical and scientific associations and academic or other...

2008-07-18 15:00:15

By Tom Fontaine, Beaver County Times, Pa. Jul. 18--MOON TWP. -- The pharmaceutical company GlaxoSmithKline will move its weight-loss and smoking-cessation national marketing groups from Moon Township to Parsippany, N.J., by the end of summer as part of a company reorganization. The two groups, which market brands such as Alli for weight loss and Nicoderm and Nicorette for smoking cessation, will "be managed under the single umbrella of a new unit that we will call behavioral sciences,"...

2008-07-09 21:00:08

LIVERPOOL PRIMARY CARE TRUST OFFER HEALTH ADVICE YOU CAN REALLY TRUST Mark Jones Is Lifestyles Manager at Liverpool City Council and a qualified personal trainer with extensive experience relating to fitness I training. DrKaty Gardner Is an experienced doctor who has been practicing as a GP for i 30 years and can answer all your generalhealth questions. Shirley Judd Is a registered dietitian who was Chief Dietitian at the Royal Liverpool University Hospital before moving to...

2008-07-09 12:00:49

WASHINGTON, July 9 /PRNewswire-USNewswire/ -- In a congressional hearing Secretary of Veterans Affairs James B. Peake, M.D., discussed the safety and importance of the research programs operated by the Department of Veterans Affairs (VA) as well as an absolute commitment to its patients, while expressing regret that even a single veteran would feel improperly treated or misused. "VA has an outstanding research program, and has been innovative in its protection of human research subjects,"...

2007-10-04 06:00:35

By Sharma, Manoj For facilitating abandonment of risky behaviors, alcohol and drug educators are always looking for newer approaches and theories. One such theory that has not been widely used in alcohol and drug education but holds promise is the Precaution Adoption Process Model (PAPM). PAPM was first suggested by Weinstein (1988). He argued that most traditional behavioral theories apply only to people who are engaged by the threat and do not take into account different stages in which...

2006-08-15 07:20:00

NEW YORK -- Varenicline, a non-nicotine drug designed specifically for smoking cessation, appears to be safe and effective according to a study in the Archives of Internal Medicine. Varenicline is FDA-approved and marketed by Pfizer as Chantix. It binds to a nicotine receptor that's believed to trigger the rewarding effects felt with smoking. Because varenicline competes more strongly than nicotine to bind to the receptor, yet has less of a rewarding effect, the investigators figured that it...


Word of the Day
caparison
  • A cloth or covering, more or less ornamented, laid over the saddle or furniture of a horse, especially of a sumpter-horse or horse of state.
  • Clothing, especially sumptuous clothing; equipment; outfit.
  • To cover with a caparison, as a horse.
  • To dress sumptuously; adorn with rich dress.
This word ultimately comes from the Medieval Latin 'cappa,' cloak.
Related